Revenue Update on Cambrex Corporation(NYSE:CBM)

Cambrex Corporation(NYSE:CBM) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Feb 3, 2017. Company reported revenue of $177.866M. Analysts estimated a revenue of $174.900M. The revenues were 1.7% above the estimates. Earnings per share were $1.23. The reported EPS was above estimates by 17.14%. Analysts had estimated an EPS of $1.05.

Cambrex Corporation (CBM) shares turned negative on Tuesdays trading session with the shares closing down -1.5 points or -2.66% at a volume of 4,64,216. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $56.3. The peak price level was also seen at $56.3 while the days lowest was $54.6. Finally the shares closed at $54.8. The 52-week high of the shares is $62.5 while the 52-week low is $29.5. According to the latest information available, the market cap of the company is $1,773 M.

Several Insider Transactions has been reported to the SEC. On Dec 15, 2016, Shawn Cavanagh (EVP & COO) sold 30,000 shares at $53.58 per share price.Also, On Nov 15, 2016, Gregory Sargen (Executive Vice President & CFO) sold 22,500 shares at $52.02 per share price.On Nov 14, 2016, Steven M Klosk (President & CEO) sold 50,000 shares at $50.87 per share price, according to the Form-4 filing with the securities and exchange commission.

Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company’s customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs) pharmaceutical intermediates and to a lesser extent other fine chemicals. Cambrex has three operating segments which are manufacturing facilities that have been aggregated as one reportable segment.

Share this post

Leave a Reply